Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment - Wikidata - wikimedia - TriplyDB

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

http://www.wikidata.org/entity/Q26738944

about

Which therapies will move to the front line for multiple myeloma?Cancer immunotherapy: Breakthrough or "deja vu, all over again"?Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

P2860

Q38733592-497D48CE-F8FC-4731-A40B-7EC919350125 Q39390619-A440CC1D-D362-4061-9F8A-7BA48738C42A Q42660142-B38E1E90-CA74-4C74-A36C-C71B4BC5464D Q47221234-2C791FA0-381D-4D3B-B30E-C342B542C8F8 Q47418005-C1515FAF-BBB8-4A41-BF97-CCF3E79E362B Q47865755-778E5288-69EE-44A7-8CE1-3B9B00FBC00D Q48255324-1B9045D9-7CA6-4C31-B5F1-0ADB6C795C08 Q49830211-CD951BDB-738B-4091-9F5B-95E0397F1CC5

P2860

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

http://www.wikidata.org/entity/Q26738944

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@ast

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@en

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@nl

type

label

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@ast

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@en

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@nl

prefLabel

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@ast

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@en

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@nl

P1433

Q26738944-A59FBE30-7F9F-47CA-840A-EF39D0000BE8

P1476

Q26738944-0B1998BB-85E1-414E-823A-C186D6394710

P2093

Q26738944-822B0F5C-6FEA-429C-B386-CD813CC0AE10

Q26738944-BB561400-ACA8-4624-98DC-80C74CFB1DB3

P2860

Q26738944-008DCA6C-D1A2-4C0A-8C55-3E3F5BCD348C

Q26738944-020420A9-D1F5-469B-B4FD-BAC110C4A8F7

Q26738944-03983F6B-B385-487C-A62D-DA603033D178

Q26738944-09C2E5BD-633F-4698-B8DF-9BE1160CF12D

Q26738944-0BDCD2D3-E6AA-4227-813D-17B091DCBA35

Q26738944-0CE93516-1181-4563-B9FE-198E30BA72E8

Q26738944-12082A8E-5BCB-43FE-93D5-E5B58A83EEDA

Q26738944-1864171A-71FC-4941-983A-BE63E27CDB13

Q26738944-2112E7F7-5EC0-4A6A-91EF-87DCF04A7913

Q26738944-4DF8517E-BC76-4430-9EFA-B8D6E39D0D39

P304

Q26738944-306CC20A-A412-4BBE-8D43-96A0516F5F86

P31

Q26738944-FD052C2A-A3D3-41B0-B9BE-57F20ECE58EF

P356

Q26738944-7A97F796-CEE5-408A-9355-8B1BA388B12D

P407

Q26738944-F75FE8A4-9132-4AAF-9188-ABA94C70B8A3

P433

Q26738944-54BC936D-C000-482F-92B0-B941C30B5B9B

P478

Q26738944-220EDFE6-D4CA-4D78-B21C-422FA36DB0CF

P577

Q26738944-0EF69747-0D17-4F45-971F-C3A248328A98

P698

Q26738944-0EFD6C21-2EC3-4B7B-90BE-057EC0AC224D

P921

Q26738944-09745F4C-5A89-4FEC-BB16-CE37A5F2A66A

P932

Q26738944-4C79F4D9-7989-41ED-AF31-8206B7EDCEFE

P356

2040620716652862

P1433

Therapeutic advances in hematology

P1476

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

@en

P2093

Eli Muchtar

http://www.w3.org/2001/XMLSchema#string

Hila Magen

http://www.w3.org/2001/XMLSchema#string

P2860

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease

Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor

Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

SLAM-family receptors: immune regulators with or without SAP-family adaptors.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

P304

187-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620716652862

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27493709

http://www.w3.org/2001/XMLSchema#string

P921

P932

4959642

http://www.w3.org/2001/XMLSchema#string